Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Gastrointestinal 2

Conditions

Uterine Cervical Neoplasms 12Papillomavirus Infections 11Neoplasms 10Breast Neoplasms 9Uterine Cervical Dysplasia 7Persistent Infection 5Condylomata Acuminata 5Prostatic Neoplasms 4Melanoma 4Anus Neoplasms 4Vulvar Neoplasms 3Lung Neoplasms 3Herpes Zoster 3Glioblastoma 3Carcinoma, Non-Small-Cell Lung 3Vaginal Neoplasms 2Sarcoma 2Neuroblastoma 2Neoplasm Metastasis 2Influenza, Human 2HIV Infections 2Glioma 2Colonic Neoplasms 2Breast Neoplasms, Male 2Wilms Tumor 1Whooping Cough 1Waldenstrom Macroglobulinemia 1Triple Negative Breast Neoplasms 1Tetanus 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

Radiotherapy 11Brachytherapy 8fludarabine 5Radiation 5Magnetic Resonance Spectroscopy 5Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 5Cyclophosphamide 5aldesleukin 4Surveys and Questionnaires 4Cisplatin 4fludarabine phosphate 3durvalumab 3Vaccines, Synthetic 3Radiosurgery 3Papillomavirus Vaccines 3Paclitaxel 3Methods 3Early Intervention, Educational 33-aminopyridine-2-carboxaldehyde thiosemicarbazone 3tremelimumab 2entinostat 2aflibercept 2Vaccines 2Trastuzumab 2Topotecan 2Therapeutics 2Surgical Procedures, Operative 2Psychiatric Rehabilitation 2Platinum 2Palliative Care 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Vaginal Neoplasms × Vaccines × Clear all
NCT05680454 2023-01-17

A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine

Beijing Health Guard Biotechnology, Inc

Phase 1 Completed
160 enrolled
GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT05662020 2022-12-27

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Beijing Health Guard Biotechnology, Inc

Phase 3 Active not recruiting
2,750 enrolled
GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡